Valuation: ThermoGenesis Holdings, Inc.

Capitalization 11.09K 9.49K 8.84K 8.18K 15.18K 951K 16.9K 106K 40.39K 444K 41.6K 40.75K 1.62M P/E ratio 2022
-0.16x
P/E ratio 2023 -0.08x
Enterprise value 9.29M 7.95M 7.41M 6.85M 12.72M 797M 14.16M 88.59M 33.83M 372M 34.85M 34.14M 1.36B EV / Sales 2022
0.97x
EV / Sales 2023 1.18x
Free-Float
71.98%
Yield 2022 *
-
Yield 2023 -
More valuation ratios * Estimated data
Dynamic Chart
Current year 0
Extreme 0
0
1 year 0
Extreme 0
0.3
3 years 0
Extreme 0
16.65
5 years 0
Extreme 0
337.5
10 years 0
Extreme 0
7,110.01
More quotes
Manager TitleAgeSince
Chief Executive Officer 54 2016-11-02
Investor Relations Contact - -
Director TitleAgeSince
Chairman 54 2016-11-02
Director/Board Member - 2023-07-13
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-99.00%-.--% - - 15
+2.15%+2.79%-6.14%+1.63% 25.33B
-1.73%-1.70%-19.38%-23.24% 6.85B
+0.31%-.--%-.--%+46.43% 3.25B
+4.96%+2.51%-46.27%-46.99% 2.55B
-2.41%-3.18%+207.59% - 2B
+1.38%-0.75%+46.94%+83.86% 1.6B
0.00%+4.96%+58.66%+214.87% 1.55B
-1.26%-1.04%-39.76%-20.70% 1.52B
+3.49%+0.78%+47.88%-18.39% 1.28B
Average -9.09%+0.22%+27.72%+29.68% 4.59B
Weighted average by Cap. +1.29%+0.22%+3.83%+7.41%
See all sector performances

Financials

2022 2023
Net sales 10.48M 8.97M 8.36M 7.73M 14.35M 899M 15.97M 99.93M 38.16M 420M 39.31M 38.51M 1.54B 9.44M 8.08M 7.53M 6.96M 12.93M 810M 14.39M 90.04M 34.39M 378M 35.42M 34.69M 1.38B
Net income -11.27M -9.64M -8.99M -8.31M -15.42M -966M -17.17M -107M -41.03M -452M -42.26M -41.4M -1.65B -17.98M -15.38M -14.33M -13.25M -24.6M -1.54B -27.39M -171M -65.44M -720M -67.41M -66.03M -2.63B
Net Debt 6.89M 5.89M 5.49M 5.08M 9.43M 591M 10.49M 65.66M 25.08M 276M 25.83M 25.3M 1.01B 9.28M 7.94M 7.4M 6.84M 12.7M 796M 14.14M 88.48M 33.79M 372M 34.81M 34.09M 1.36B
More financial data * Estimated data
Logo ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. The Company provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, the PXP platform for point-of-care cell-based therapies and X-Series products for cell processing services. Its product lines include Clinical Bio-Banking Applications, Point-of-Care Applications and Cell Processing. Its Clinical Bio-Banking Applications include AXP II Automated Cell Separation System and BioArchive Automated Cryopreservation System. Its Point-of-Care Applications include PXP Point-of-Care System, and PXP-1000 System. Its Cell Processing includes X-Series Products for general laboratory use: X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The Company markets and sells its medical device products through independent distributors.
Employees
25
More about the company
Date Price Change Volume
25-07-09 - $ - 29

Delayed Quote OTC Markets, June 17, 2025 at 12:25 pm EDT

More quotes

Quarterly revenue - Rate of surprise